A key U.S. House Committee today will take up the health spending portions of a GOP-backed budget reconciliation plan, which [...] …
Month: May 2025
U.S. Rep. Earl “Buddy” Carter (R-Ga.), a longtime 340B critic, is running for U.S. Senate in 2026—a move that could [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Lawmakers in three New England states have recently advanced 340B contract pharmacy access bills—two of which are scheduled for pivotal [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
President Donald Trump directed his administration Monday to use its trade, regulatory and enforcement powers to establish a “most-favored nation” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Oklahoma state senators today overwhelmingly passed a 340B contract pharmacy access and pharmacy benefit manager (PBM) “nondiscrimination” bill, sending it [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four drugmakers recently announced they will exempt additional states from their 340B contract pharmacy restrictions in response to a flurry [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four major drugmakers and an industry vendor are urging a federal judge not to delay ruling on their 340B rebate [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The term “specialty medication” is often associated with a hefty price tag and numerous challenges related to claims processing. While this may be true in certain circumstances, organizations providing or considering offering specialty medications can still successfully navigate these complexities with
…
Just one day after passing a provider-backed contract pharmacy access and hospital reporting bill, Colorado lawmakers failed to advance a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A California think tank, and an influential drug industry trade group that funds it, are raising concerns that President Donald [...] …